A5008442669- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Immune cells in cancer
- Multiple and Secondary Primary Cancers
- Cancer therapeutics and mechanisms
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Management of metastatic bone disease
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Spine and Intervertebral Disc Pathology
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neuroblastoma Research and Treatments
Institut Paoli-Calmettes
2016-2025
Institut Pprime
2007-2023
Centre Antoine Lacassagne
2023
Intergroupe Francophone de Cancérologie Thoracique
2020-2023
Centre de Recherche en Cancérologie de Marseille
2006
Inserm
2006
Hôpital Pasteur
2004
Institut Bergonié
2004
Clinique Pasteur
2004
Centre Hospitalier Universitaire de Besançon
2004
// Michaël Duruisseaux 1 , Benjamin Besse 2 Jacques Cadranel 3 Maurice Pérol 4 Bertrand Mennecier 5 Laurence Bigay-Game 6 Renaud Descourt 7 Eric Dansin 8 Clarisse Audigier-Valette 9 Lionel Moreau 10 José Hureaux 11 Remi Veillon 12 Josiane Otto 13 Anne Madroszyk-Flandin 14 Alexis Cortot 15 François Guichard 16 Pascaline Boudou-Rouquette 17 Alexandra Langlais 18 Pascale Missy 19 Franck Morin Denis Moro-Sibilot Centre Hospitalier Universitaire Grenoble Alpes, Thoracic...
Patients with advanced non-small-cell lung cancer (NSCLC) treated immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The vaccine OSE2101 may invigorate antitumor-specific responses ICB failure. objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients. a two-step open-label study the compared standard-of-care (SoC) chemotherapy (CT). human leukocyte antigen (HLA)-A2-positive NSCLC...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Osimertinib established as a standard of care patients with common sensitizing EGFR-mutant advanced non–small-cell...
Farmer's lung disease (FLD) is common in the east of France. In absence primary recognized FLD agent, Saccharopolyspora rectivirgula, its etiology remains unknown. A prospective case-control study was performed to find this area. Eleven patients were matched with 11 healthy control farmers. Twenty-two urban subjects constituted nonexposed group. Microorganisms from cowshed air and fodder identified counted. The antigens microorganisms most frequently isolated at 22 farms used for serological...
The benefit of precision medicine based on relatively limited gene sets and often-archived samples remains unproven. PERMED-01 (NCT02342158) was a prospective monocentric clinical trial assessing, in adults with advanced solid cancer, the feasibility impact extensive molecular profiling applied to newly biopsied tumor sample targeted NGS (t-NGS) largest panel date whole-genome array-comparative genomic hybridization (aCGH) assessment single-gene alterations clinically relevant...
Abstract Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors pembrolizumab in patients with advanced NSCLC. Experimental Design: We used high-dimensional mass cytometry (CyTOF) baseline blood samples NSCLC treated pembrolizumab. CyTOF data were analyzed by machine-learning algorithms (Citrus, tSNE) and...
Hypersensitivity pneumonitis (HP) is characterized by a lymphocytic alveolitis, classically delineated an increase of CD8+ lymphocytes, with inversion the CD4+/CD8+ ratio. The aim this study both to describe yield and cell bronchoalveolar lavage (BAL) profile revisit assumption low BAL CD4/CD8 ratio in diagnosis HP. A multicentric was conducted on 139 patients who fulfilled standardized diagnostic criteria HP, mainly affected farmers lung. Mean total count fluid 594 ± 401.103 cells /ml....
Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. The objective this study was compare incremental cost-effectiveness ratios strategies initiation in NSCLC: clinically guided (nonsmoking females with adenocarcinoma received erlotinib; all other patients docetaxel) biologically selection (patients epidermal growth factor receptor (EGFR)...
Small cell lung cancer (SCLC) has a tendency towards recurrence and limited survival. Standard-of-care in 1st-line is platinum-etoposide chemotherapy plus atezolizumab or durvalumab,based on landmarkclinical trials.IFCT-1905 CLINATEZO nationwide, non-interventional, retrospectivestudy of patients with extensive-SCLC receivingatezolizumab as part French Early Access Program. Objectives were to analyse effectiveness,safetyand subsequent treatments.The population analyzed included 518 who...
Molecular profiling is considered a standard of care in advanced NSCLC. A comprehensive next-generation sequencing panel can discover somatic or germline BRCA1/2 mutations that are new druggable molecular alterations. However, the phenotypic and potential therapeutic relevance mutation NSCLC remains poorly defined.From April 2014 to March 2017, 600 newly diagnosed, EGFR/ALK negative patients with were enrolled SAFIR02-Lung trial. was done at study entry on archival tissue frozen collected...
Abstract Purpose: Double inhibition of epidermal growth factor receptor (EGFR) using a tyrosine kinase inhibitor plus monoclonal antibody may be novel treatment strategy for non–small cell lung cancer (NSCLC). We assessed the efficacy and toxicity afatinib + cetuximab versus alone in first-line advanced EGFR-mutant NSCLC. Patients Methods: In this phase II, randomized, open-label study, patients with stage III/IV EGFR-positive NSCLC were randomly assigned (1:1) to receive (group A) or A C)....
4118 Background: The survival of patients (pts) with locally advanced or metastatic pancreatic cancer could be improved by the addition P to standard chemotherapy G. Methods: primary objective was compare time treatment failure (TTF) pts treated GP versus Secondary objectives were toxicity, overall (OST), quality-adjusted without symptoms toxicity (Q-TWiST analysis), and quality life (EORTC QLQ-C30 questionnaire) between arms assess response rate (ORR) duration in two arms. Chemonaive age...
ALK rearrangement and EGFR / KRAS mutations constitute the primary biomarkers tested to provide targeted or nontargeted therapies in advanced nonsmall cell lung cancer (NSCLC) patients. Our objective was assess cost-effectiveness of biomarker testing for NSCLC. Between 2013 2014, 843 treatment-naive patients were prospectively recruited at 19 French hospitals into a longitudinal observational cohort study. Two strategies compared, i.e. with “at least one status known” known”, addition “no...